Valuation: Spero Therapeutics, Inc.

Market Cap 59.98M 53.8M 49.17M 44.88M 84.56M 5.64B 87.23M 593M 236M 3.01B 225M 220M 9.5B P/E 2026 *
-1.78x
P/E 2027 * -9.81x
Enterprise Value 59.98M 53.8M 49.17M 44.88M 84.56M 5.64B 87.23M 593M 236M 3.01B 225M 220M 9.5B EV / Sales 2026 *
232x
EV / Sales 2027 * -
Free-Float
77.34%
Yield 2026 *
-
Yield 2027 * -
1 day+0.98%
1 week-2.83%
Current month-2.83%
1 month-13.45%
3 months-18.90%
6 months-59.29%
Current year-55.79%
1 week 0.96
Extreme 0.961
1.11
1 month 0.96
Extreme 0.961
1.24
Current year 0.96
Extreme 0.961
3.08
1 year 0.96
Extreme 0.961
3.08
3 years 0.51
Extreme 0.5052
3.22
5 years 0.51
Extreme 0.5052
17.82
10 years 0.51
Extreme 0.5052
23.64
Manager TitleAgeSince
Chief Executive Officer 47 2025-01-09
Chief Tech/Sci/R&D Officer 69 2026-07-26
Chief Operating Officer 58 2023-01-31
Director TitleAgeSince
Chairman 69 2013-12-31
Director/Board Member 62 2015-08-31
Chairman 56 2025-01-09
Date Insider Type Main position Quantity % Market Cap. Importance
8/3/26 Free

Chief Technology Officer

486,986 0.8411%
5/4/26 Sell

Chief Executive Officer

-25,240 0.0436%
2/6/26 Sell

Chief Executive Officer

87,917 0.1560%
Change 5-day change 1-year change 3-year change Capi.($)
+0.98%-2.83%-56.90%-11.21% 59.4M
-4.83%+3.51%+53.62%+61.75% 69.4B
-1.34%+2.98%+24.79%+100.18% 57.62B
+0.02%+1.07%+10.63%+76.66% 57.24B
+5.09%+9.89%+22.45%+107.48% 44.03B
+2.62%+1.68%+28.91%+37.01% 43.65B
+8.24%+0.51%+213.26%+792.66% 38.08B
-1.86%+10.13%+26.82%+53.22% 36.31B
-2.97%-9.84%+88.86%+76.17% 32.61B
-2.18%+7.06%+36.06%-4.95% 25.47B
Average +0.38%+3.52%+44.85%+128.90% 40.45B
Weighted average by Cap. +0.05%+4.26%+51.71%+136.64%

Financials

2026 *2027 *
Net sales 258K 231K 211K 193K 364K 24.25M 375K 2.55M 1.02M 12.94M 968K 948K 40.85M -
Net income -33.46M -30.01M -27.42M -25.03M -47.16M -3.14B -48.65M -331M -132M -1.68B -126M -123M -5.3B -51.5M -46.19M -42.21M -38.53M -72.6M -4.84B -74.89M -509M -203M -2.58B -193M -189M -8.15B
Net Debt - -
Projected Income Statement - Annual - Spero Therapeutics, Inc.
Logo Spero Therapeutics, Inc.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Employees
25
Date Price Change Volume
26-11-06 $1.030 +0.98% 186,667
26-11-05 $1.020 -4.67% 712,401
26-11-04 $1.070 +2.88% 210,266
26-11-03 $1.040 0.00% 204,353
26-11-02 $1.040 -1.89% 433,564
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Spero Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.030USD
Average target price
5.333USD
Spread / Average Target
+417.80%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Spero Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. SPRO Stock